Compare Cassava Sciences Inc (FLNA) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs KB Financial Group, Inc. — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while KB Financial Group, Inc. trades at $121.96 (market cap $44.15B). The key difference: KB Financial Group, Inc. is far larger — about 1120.6× Cassava Sciences Inc's market cap, and KB Financial Group, Inc. pays a 2.65% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and KB Financial Group, Inc. for 33 Days on average.
| FLNA | KB | |
|---|---|---|
Market Cap | $39.40M | $44.15B |
Volume | 759,018 | 131,395 |
Sector | Health | Financials |
52-Week High | $4.64 | $132.88 |
52-Week Low | $0.68 | $77.50 |
Typical Hold Time | 37 Days | 33 Days |
Enterprise Value | -$43.28M | $215.53T |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
KB Financial Group trades at $124.73, showing minimal daily movement with a slight decline of 0.02%. The stock exhibits neutral technical signals while maintaining strong fundamental performance with consistent earnings beats and improving profitability. Recent quarterly results exceeded expectations, with Q2 2026 EPS of $3.79 beating estimates of $3.51. The company demonstrates solid revenue growth, climbing from $17.77T in 2022 to $21.23T in 2025, with net income margins expanding to 27.47%.
KB presents an attractive value proposition with a P/E of 9.92 and P/B of 0.97, trading below book value. Analyst sentiment is mixed with 33% buy ratings but strong institutional interest. Key risks include banking sector volatility and interest rate sensitivity, while opportunities lie in South Korea's outperforming market and the company's expanding non-banking activities driving fee income growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
